• Pharvaris will present Phase 3 CHAPTER-3 results for deucrictibant XR at the ACAAI meeting on Nov. 14, 2026.
• The investigational oral treatment met its primary and all secondary efficacy endpoints, significantly reducing hereditary angioedema attacks versus placebo.
• Patients reported improved quality of life; the treatment was generally well tolerated, with no treatment-related serious adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121028PRIMZONEFULLFEED9876483) on November 12, 2026, and is solely responsible for the information contained therein.